半乳凝素3在溃疡性结肠炎结肠组织和血清中的表达及其意义

背景：半乳凝素3(galectin-3)是一种具有广泛免疫调节作用的内源性凝集素,在炎症反应、自身免疫、肿瘤发生中发挥重要作用,但在溃疡性结肠炎（UC）中的表达及其与活动性的关系尚不明确。目的：检测UC患者结肠组织和血清galectin-3的表达,并进一步探讨galectin-3与疾病活动性之间的关系。方法：收集2019年3月—2019年12月郑州大学第二附属医院诊治的UC结肠镜活检组织33例,以20名结肠癌癌旁正常组织作为对照,采用免疫组化SABC法检测galectin-3的表达。选取24例UC血清标本和20名健康对照组血清标本,以ELISA法检测galectin-3水平。结果：UC患者结肠组织galectin-3阳性表达率显著低于结肠癌癌旁正常对照组,差异有统计学意义（P<0.05）;轻度UC患者阳性表达率显著高于中重度UC患者,差异有统计学意义（P<0.05）;缓解期UC患者显著高于活动期UC患者,差异有统计学意义（P<0.05）。UC患者血清galectin-3水平显著高于健康对照组,差异有统计学意义（P<0.05）;中重度UC患者血清galectin-...     

急性胰腺炎大鼠血清MIF表达变化及其与TNF-α的相关性

目的观察急性胰腺炎大鼠血清巨噬细胞移动抑制因子（MIF）表达变化,并探讨其与血清TNF-α的相关性。方法 66只雄性Wistar大鼠,随机分为正常对照组6只、急性水肿性胰腺炎（AEP）组30只和急性坏死性胰腺炎（ANP）组30只。AEP和ANP组分别于造模后1、3、6、9和12 h处死6只动物,采集血清。用ELISA法测定血清MIF和TNF-α水平。结果 AEP和ANP大鼠血清MIF和TNF-α水平均显著高于正常对照组（P均〈0.05）,AEP大鼠血清MIF和TNF-α水平均显著低于ANP大鼠（P均〈0.05）。AEP和ANP大鼠血清MIF水平与TNF-α水平均呈正相关关系（r分别为0.582、0.652,P均〈0.05）。结论急性胰腺炎大鼠血清MIF明显升高,且与血清TNF-α水平呈正相关。     

PICK1在心肌梗死大鼠血清、心肌组织中的表达及意义

目的研究急性心肌梗死大鼠血清及心肌组织中蛋白激酶Cα相互作用蛋白（PICK1）的表达及意义。方法将43只清洁级Wistar大鼠随机分为3组：正常对照组8只,心肌梗死模型组20只,假手术组15只,心肌梗死模型组采用左冠状动脉前降支结扎法构建模型,假手术组仅在左冠状动脉主干下打一松节,正常对照组不做任何干预。采用酶联免疫吸附试验（ELISA）及免疫印迹法（Western—blot）分别检测1d,3d,7d各组大鼠血清和心肌组织中PICK1的表达水平。结果与正常对照组及假手术组相比,心肌梗死模型组大鼠建模后1d血清PICK1水平略有增高,但差异无统计学意义（P〉0．05）;自3d开始,模型组大鼠血清PICK1水平明显高于假手术组及正常对照组（P〈0．05）;7d时,模型组血清PICK1高于假手术组及正常对照组（P〈0．05）,但与3d时相比,差异无统计学意义（P〉0．05）。与正常对照组及假手术组相比,心肌梗死模型组大鼠1d,3d,7d时心肌组织PICK1蛋白的水平显著增高,差异有统计学意义（P〈0．05）,模型组各时间PICK1蛋白的表达无统计学意义（P〉0．05）;假手术组与正常对照组PICK1蛋白水平无统计学意义（P〉0．05）。结论PICK1在心肌梗死大鼠血清及心肌组织中表达增高,可能在心肌缺血再灌注损伤中发挥一定的作用。     

电针对非酒精性脂肪性肝炎大鼠胰岛素抵抗及血清瘦素水平的影响

目的：应用电针刺激SD大鼠肝俞、足三里、丰隆、太冲穴,观察其对高脂饮食所致的非酒精性脂肪性肝炎（NASH）大鼠血清胰岛素抵抗（IR）和瘦素（Leptin）水平的影响。方法：40只SD大鼠随机分为正常组、模型组、电针组和西药组,每组10只。除正常组外,其他3组大鼠均以范建高经典造模法造模。电针组和西药组大鼠在造模12周后分别行针灸和西药治疗。16周时将所有大鼠断头处死,用HE染色光镜下观察肝组织的病理改变。经下腔静脉采血,迅速按常规分离血清,采用酶法检测血清空腹血糖（ FBG）及采用放射免疫分析法测定空腹血清胰岛素（ FINS）,计算胰岛素抵抗指数;采用ELISA法测定血清Leptin水平。结果：正常组大鼠空腹血糖与其他各组比较,差异无统计学意义（P＞0.05）,模型组大鼠IR比正常组显著增高（P＜0.01）;比电针组增高（P＜0.05）;电针组较西药组有下降趋势,但两者比较差异无明显性意义（ P＞0.05）。正常组大鼠与模型组比较,血清Leptin水平显著降低（ P＜0.05﹚;电针组与药物组比较,血清Leptin水平有下降趋势,但差异无统计学意义（ P＞0.05）。结论：电针治疗能够降低非酒精性脂肪性肝炎大鼠血清Leptin水平,减轻脂质过氧化,是其治疗NASH的重要机制。     

肝癌组织和血清中半乳糖血凝素-3的表达及其意义

目的 研究人肝癌组织及血清中半乳糖血凝素-3(galectin-3)的表达及其临床意义.方法 免疫组织化学法检测46例肝癌及其癌旁组织中galectin-3,分析galectin-3表达水平与各临床参数之间的关系; 酶联免疫吸附法检测不同肝病患者及正常人血清中galectin-3浓度,同步比较galectin-3浓度与甲胎蛋白(AFP)、γ-谷氨酰转移酶同工酶Ⅱ(GGT-Ⅱ)诊断肝癌的灵敏性及特异性,探讨3项指标对肝癌的互补诊断价值.用Stata8.0及SPSS15.0统计软件对结果进行统计分析.采用配对设计四格表假设检验、秩和检验、χ2检验、Fisher's确切概率法、Spearman等级相关方法.结果 (1)galectin-3在肝癌组织中的表达阳性率为78.2%,癌旁组织为15.2%,χ2=92.000,P<0.01,差异有统计意义.其表达水平与分化程度相关,分化程度越低表达水平越高;(2)根据ROC曲线,当确定诊断界值为0.62μg/L时,galectin-3阳性率在肝癌患者中为64.5%,肝硬化患者中为3.1%、慢性肝炎患者及正常人中均为0,P<0.05(Fisher's确切概率法);(3)肝癌患者血清中galectin-3与AFP、GGT-Ⅱ均无相关性,联合检测3项指标对肝癌诊断有互补性,可使诊断敏感性提高至94.7%.结论 galectin-3在肝癌组织中高表达,与肝癌的分化程度相关,可能与肝癌的发生和发展有关;肝癌患者联合检测血清galectin-3、AFP和GGT-Ⅱ可提高对肝癌诊断的敏感性,galectin-3有望成为新的肝癌标记物.

Abstract：

Objective To study the expression of Galectin-3 in human hepatocellular carcinoma (HCC) tissues and the clinical value of serum Galectin-3 in the diagnosis of hepatocellular carcinoma. Methods Immunohistochemistry method was used to detect the expression of Galectin-3 in the 46 pairs of HCC tissues and their paracancerous tissues. The relationship between expression levels of Galectin-3 and clinical parameters was analyzed. Serum Galectin-3 in different liver diseases were measured with ELISA. The sensitivity and specificity of galectin-3, alpha fetoprotein (AFP) and gamma-glutamyltranspeptidase Ⅱ (GGT-Ⅱ)for diagnosis of HCC were compared and the complementary diagnostic values of Galectin-3 and AFP and GGT-Ⅱ for HCC were studied. Results (1) The positive rate of Galectin-3 in the tissue of HCC was 78.2%, dramatically higher than that in paracancerous tissues (15.2%) (P < 0.01). The expression levels were correlated with differentiation and with the high expression in poor differentiation tissues; (2) Based on ROC curve, the cut-off of serum Galectin-3 for HCC diagnosis was set as 0.62 μg/L, the serum galectin-3 positive rate was 64.5% in HCC cases, which was apparently higher than that in liver cirrhosis, chronic hepatitis and healthy persons (P < 0.05); (3) Serum Galectin-3 was not correlated with AFP and GGT-Ⅱ. Combined determination of the three markers had the complementary diagnostic value for HCC and might increase the diagnostic sensitivity to 94.7%. Conclusion Galectin-3 is overexpressed in HCC tissues and is correlated with the tumor differentiation, suggesting that Galectin-3 may be associated with the carcinogenesis and development of HCC. Serum galectin-3 increases in the HCC cases and combined determination of serum Galectin-3, AFP and GGT-Ⅱ can increase the diagnostic efficiency for HCC. Galectin-3 could be a novel serum tumor marker for HCC.     

肝细胞癌患者血清血管生成素-2含量的检测及其临床意义

目的：讨论血管生成素-2（Ang-2）在肝细胞癌（HCC）患者血清中的表达水平及其临床意义。方法：用ELISA法分别检测51例HCC患者、26例良性肝病患者及30例正常对照者血清中Ang-2的表达水平,并检测HCC患者术后各随访组及肿瘤复发组患者血清Ang-2的表达水平。分析血清Ang-2含量与HCC病理特征的关系。结果：HCC组及肿瘤复发组患者血清Ang-2含量为[（2431.1±1084.2）ng/L、（2046.5±868.0）ng/L],较良性肝病组和正常对照组[（1098.6±464.3）ng/L、（1028.4±452.3）ng/L]显著增高（P〈0.01）,良性肝病组患者血清中Ang-2含量与正常对照组比较无明显增高,差异无显著性意义（P〉0.05）;术后随访各组患者Ang-2含量较术前显著降低（P〈0.01）。HCC患者的血清Ang-2含量与HCC门静脉癌栓形成、肿瘤分化程度、病理分期均呈显著正相关（P〈0.01）,与肿瘤大小无关（P〉0.05）。结论：血清Ang-2表达水平可作为一种新的具有临床应用价值的肿瘤标志物,有助于HCC的早期诊断、疗效评价、预后预测及高危对象的监测。     

Galectin-3在甲状腺结节中的表达

目的研究galectin-3在甲状腺结节中的表达.方法应用免疫组化及RT-PCR方法检测甲状腺标本中galectin-3表达.结果无论采用免疫组化或RT-PCR方法,甲状腺癌组织的galectin-3表达率均较高（阳性率为89.7%和91.7%）,不同类型的癌组织中有较大差异,其中乳头状癌和滤泡状腺癌具有较高水平的表达（阳性率100%）.有淋巴结转移者galectin-3表达水平高于无淋巴结转移者.在良性甲状腺结节及正常甲状腺组织,采用免疫组化方法检测的25份甲状腺腺瘤标本和13份结节性甲状腺肿标本仅3例呈阳性,余均为阴性,10份正常甲状腺组织及25份癌旁组织均未发现galectin-3表达.结论galectin-3可作为鉴别良、恶甲状腺疾病的一个较有价值的肿瘤指标.     

肝细胞癌患者外周血单个核细胞Foxp3 mRNA水平变化*

目的 检测初发现未治疗肝细胞癌（HCC）患者外周血单个核细胞（PBMCs）中 Foxp3 mRNA水平变化及其与血清AFP水平的关系。方法 在HCC患者60例和健康人20例,采用RT-PCR法检测PBMCs中Foxp3 mRNA水平,常规检测血清AFP水平。结果 HCC患者和健康对照组外周血Foxp3 mRNA水平分别为（0.976±0.073）和（0.772±0.083）,差异有统计学意义（P<0.01）;经Pearson相关性分析显示,HCC患者外周血Foxp3 mRNA水平与AFP水平呈正相关（r＝0.226,P＝0.025）。结论 HCC患者PBMCs 中Foxp3水平明显升高,对肿瘤的发生发展可能具有一定的预测作用。     

肝癌患者血清microRNA-21水平变化

目的：分析不同肝病患者血清microRNA-21（miR-21）水平,以探讨miR-21对肝细胞癌（HCC）的诊断价值。方法以实时定量逆转录PCR法检测正常人、慢性乙型肝炎（CHB）、肝硬化和HCC患者（各组均为25例）血清miR-21水平,分析miR-21水平与HCC临床病理学特征的关系。结果正常人、CHB和肝硬化患者血清miR-21相对水平分别为（1.1±1.7）、（2.3±2.6）和（2.8±2.5）,而HCC患者为（22.6±4.4）,显著高于前三组（P〈0.001）;HCC患者术后1w和1m血清miR-21相对水平分别为（18.4±3.5）和（3.1±2.7）,均较术前显著降低（P＜0.001）;HCC患者血清miR-21水平与肿瘤大小、癌栓以及HBV感染相关,与肿瘤分化程度、数目和血清AFP水平无相关性。结论 miR-21在HCC患者血清中显著升高,可能作为HCC早期诊断的潜在标志。     

塞来昔布对小鼠lewis肺癌模型血清galectin-3、MMP-9的影响

目的 观察塞来昔布对lewis肺癌小鼠血清galectin-3、MMP-9表达的影响.方法 C57BL/6小鼠45只随机分为正常对照组、荷瘤对照组和塞来昔布组.荷瘤对照组和塞来昔布组建立lewis肺癌模型.正常对照组和荷瘤对照组给予普通饲料喂养,而塞来昔布组自接种之日起给予含塞来昔布1 mg/g的饲料喂养.35天后测量各组皮下肿瘤的重量和肺部肿瘤转移灶的数目.并且使用ELISA检测小鼠血清MMP-9和galectin-3水平.结果 塞来昔布组皮下肿瘤重量和肺部肿瘤转移灶数量明显低于荷瘤对照组(P＜0.05);与荷瘤对照组相比,塞来昔布组血清MMP-9和galectin-3的水平明显降低(P＜0.05).结论 塞来昔布能够抑制lewis肺癌的生长和转移,其机制可能与调节血清galectin-3、MMP-9的表达有关.     

模拟失重对大鼠实验性胃溃疡氧化应激状态的影响

目的探讨模拟失重对乙酸诱导的大鼠实验性胃溃疡氧化应激状态的影响及可能机制。方法 32只SD大鼠随机分为4组,即尾部悬吊7 d组、尾部悬吊14 d组和相应的同步对照组。采用乙酸烧灼法制备大鼠慢性胃溃疡模型,造模后第3天悬吊组大鼠采用尾悬吊法建立模拟失重动物模型。游标卡尺检测胃溃疡面积,生化比色法测定大鼠血清中丙二醛(MDA)含量,超氧化物岐化酶(SOD)及谷胱甘肽过氧化物酶(GSH-Px)活性。结果与对照7 d组相比,悬吊7 d组大鼠溃疡面积显著增大(t=5.661,P<0.01);与对照14 d组比较,悬吊14 d组溃疡面积显著增大(t=4.233,P<0.01),血清MDA含量及SOD活性显著增高(t=2.641,P<0.05,t=5.758,P<0.01);与悬吊7 d组比较,悬吊14 d组溃疡面积显著减小(t=3.805,P<0.01),血清MDA含量及SOD活性显著增高。血清GSH-PX活性差异无统计学意义(P<0.05)。结论模拟失重可加重溃疡氧化应激反应,延迟溃疡愈合。     

Prognostic Significance of Serum Galectin-3 Levels in Patients with Hepatocellular Cancer and Chronic Viral Hepatitis

Background/Aim:

Galectins affect diverse physiological and pathophysiological processes such as development, inflammation, and tumor growth. We aimed to compare serum galectin-3 levels in three patient groups with chronic hepatitis B and C virus (HBV, HCV), cirrhosis secondary to HBV or HCV, and hepatocellular carcinoma (HCC) secondary to HBV or HCV and evaluate the role of galectin-3 during HCC progression.

Patients and Methods:

Nineteen patients with hepatocellular cancer, 22 patients with cirrhosis, and 24 patients with chronic hepatitis B and C were included in this study. Serum galectin-3 levels in different liver diseases were assessed by enzyme-linked immunosorbent assay.

Results:

The mean galectin-3 levels were 4.61 ng/mL (±2.32) in HCC patients, 5.68 ng/mL (±2,2) in cirrhotic patients, 1.98 ng/mL (±1.50) in chronic viral hepatitis group. There were no statistical differences between HCC and cirrhotic patients (P = 0.5), but lower in chronic hepatitis group statistically compared with cirrhosis and HCC (P < 0.001, P = 0.002, respectively). In case of cirrhotic patients, galectin-3 levels were significantly higher in patients with cirrhosis secondary to HCV compared with HBV (P = 0.03). When we evaluated galectin-3 levels in HCC patients, it was found to be 3.92 ng/mL in HCC secondary to hepatitis B and 5.37 ng/mL in HCC secondary to hepatitis C.

Conclusion:

Serum galectin-3 levels in patients with chronic HBV or HCV may guide us about progression to cirrhosis or HCC and prognosis of the disease. Especially, galectin-3 levels may be more pronounced in case of HCV.     

肝癌患者血清、癌组织中IL-6表达及其性别差异

目的观察肝细胞癌（肝癌）患者血清及癌组织中IL-6的表达及其性别差异。方法采用ELISA法检测不同性别肝癌患者术前及健康者外周血血清中的IL-6,免疫组化法检测肝癌组织中的IL-6。结果肝癌患者术前血清IL-6中位水平为4.82 pg/ml,健康者为2.31 pg/ml,两者比较,P〈0.01;男性肝癌患者血清IL-6水平为4.96pg/ml,女性为3.87 pg/ml,两者比较,P〈0.05。血清IL-6水平以3.51 pg/ml为cut-off值,诊断肝癌的敏感度与特异度分别为88.9%、87.5%;血清IL-6水平≥3.51 pg/ml者多为男性、肿瘤直径较大、血管内癌栓、肿瘤无包膜患者（P均〈0.05）。肝癌组织中IL-6阳性率为77%（69/90）,其中男性患者为84%（56/67）,女性患者为57%（13/23）,两者比较,P〈0.05。结论肝癌患者血清IL-6水平比正常健康者明显升高,男性肝癌患者血清及癌组织中IL-6的表达均高于女性患者。     

Intrahepatic cholangiocarcinoma with increased serum CYFRA 21-1 level

CYFRA 21-1 is a fragment of cytokeratin 19 (CK 19). Four patients with large intrahepatic (or peripheral) cholangiocarcinoma (CC) and high serum levels of CYFRA 21-1 (normal, ≤2 ng/ml) are reported. CYFRA 21-1 levels exceeded 9 ng/ml in all 4 patients. Carcinoembryonic antigen (CEA), was high in 1 (CEA; normal range, ≤5.0 ng/ml) and carbohydrate antigen 19-9 (CA 19-9) was high in 3 (CA19-9; normal range, ≤36 U/ml). We also measured serum levels of CYFRA 21-1 in 13 patients with hepatocellular carcinoma (HCC) more than 5 cm in diameter. Levels of CYFRA 21-1 exceeded 2 ng/ml in 9 of the HCC patients and were higher than 9 ng/ml in 2 of the HCC patients. Levels of alpha fetoprotein (AFP) and/or protein induced by vitamin K absence or antagonist II (PIVKA II) were elevated in all HCC patients (AFP, PIVKA II, respectively; normal range, ≤10.0 ng/ml and ≤0.1 AU/ml) CYFRA 21-1 levels were measured twice or three times during the clinical course in 2 CC patients and in 6 HCC patients, and increased gradually with tumor growth in the 2 CC patients and in 3 of the 6 HCC patients. Marked increases in serum CYFRA 21-1 levels in patients with large liver cancers, particularly in those with normal levels of AFP and PIVKA II, would suggest the existence of intrahepatic CC rather than HCC. (Received May 8, 1997; accepted Oct. 30, 1997)     

Gal-3与Bcl-2、层粘连蛋白受体在胰腺癌中表达的关系及意义

目的：研究Gal-3与Bcl-2、层粘连蛋白受体（LR）在胰腺癌中的表达，并探讨它们与胰腺癌的发生、发展与转移的关系以及Gal-3与Bcl-2、LR在胰腺癌中的表达之间的关系及意义。方法：应用免疫组织化学技术S－P法检测胰腺癌组织中Gal-3、Bcl-2、LR等3种蛋白质的表达，并与3者在良性胰腺组织中的表达进行对照，采用四格表x^2检验对结果进行统计学分析。结果：（1）在68例胰腺癌组织标本中，Gal-3、Bcl-2、LR表达的阳性率分别为81％（55／68）、48.5%(33/68)、55.4%(37/68)。30例良性病变胰腺组织中，Gal-3呈无或弱表达，而LR和Bcl-2呈阳性或强阳性表达，表达率各为40％（12／30）、76.7%(23/30)、83.3%（25／30），与在胰腺癌中的表达相比，Gal-3的表达水平明显下降（P＜0.01），Bcl-2与LR的表达显著升高（P＜0.01、P＜0.05）。（2）3者的阳性表达都与癌组织的分化程度无关。G al-3在转移灶中的表达水平显著升高（P＜0.05）。Gal-3的表达随着肿瘤的进展而增强，Bcl-2、LR的表达则减弱。结论：Gal-3可能与胰腺癌的发生发展及转移有关，而Bcl-2、LR可能是维持细胞正常活动的重要因子。     

Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma

The interaction between T cell immunoglobulin- and mucin-domain-containing molecule (Tim-3) expressed on T helper 1 (Th1) cells, and its ligand, galectin-9, negatively regulates Th1-mediated immune responses. However, it is poorly understood if and how the Tim-3/galectin-9 signaling pathway is involved in immune escape in patients with hepatocellular carcinoma (HCC). Here we studied the expression, function, and regulation of the Tim-3/galectin-9 pathway in patients with hepatitis B virus (HBV)-associated HCC. We detected different levels of galectin-9 expression on antigen-presenting cell (APC) subsets including Kupffer cells (KCs), myeloid dendritic cells (DCs), and plasmacytoid DCs in HCC. The highest galectin-9 expression was on KCs in HCC islets, not in the adjacent tissues. Furthermore, Tim-3 expression was increased on CD4(+) and CD8(+) T cells in HCC as compared to the adjacent tissues, and Tim-3(+) T cells were replicative senescent and expressed surface and genetic markers for senescence. Interestingly, tumor-infiltrating T-cell-derived interferon (IFN)-γ stimulated the expression of galectin-9 on APCs in the HCC microenvironment. Immunofluorescence staining revealed a colocalization of Tim-3(+) T cells and galectin-9(+) KCs in HCC. Functional studies demonstrated that blockade of the Tim-3/galectin-9 signaling pathway importantly increased the functionality of tumor-infiltrating Tim-3(+) T cells as shown by increased T-cell proliferation and effector cytokine production. Finally, we show that the numbers of Tim-3(+) tumor-infiltrating cells were negatively associated with patient survival. Conclusion: Our work demonstrates that the Tim-3/galectin-9 signaling pathway mediates T-cell senescence in HBV-associated HCC. The data suggest that this pathway could be an immunotherapeutic target in patients with HBV-associated HCC. (HEPATOLOGY 2012).     

The expressions and clinical significances of tissue and serum galectin-3 in pancreatic carcinoma

Purpose

Galectin-3, a member of the beta-galactoside-binding protein family, is involved in many biological processes, including cell proliferation, regulating cell cycle, angiogenesis, tumorigenesis, metastasis, etc. The aim of this study is to elucidate the relationship between galectin-3 and clinicopathological variables and to evaluate the clinical significance of serum galectin-3 in the diagnosis of pancreas carcinoma.

Methods

Galectin-3 expression in 78 pairs of pancreatic carcinoma tissues and the adjacent nontumorous tissues was tested by immunohistochemistry. The relationship between galectin-3 expression and clinical variables was analyzed. A sensitive method of time-resolved fluorescence immunological assay (TRFIA) for the detection of galectin-3 was established, and serum galectin-3 in cases with different pancreatic diseases was measured by TRFIA and ELISA. Further we compared the sensitivity and specificity of determining galectin-3, carcinoembryonic antigen (CEA) and carbohydrate antigen199 (CA199) for diagnosis of pancreatic carcinoma and assessed the complementary diagnostic value of galectin-3, CEA and CA199 for pancreatic carcinoma.

Results

Immunohistochemistry showed that galectin-3 expression was significantly higher in the human pancreatic carcinoma tissues than in the adjacent nontumorous tissues. The expression levels were correlated with the differentiation degree with the higher expression in poor differentiation tissues. Serum galectin-3 detected by both TRFIA and ELISA was much higher in patients with pancreatic carcinoma than in other groups. Serum galectin-3 was not correlated with CEA and CA199. Combined determination of these three markers has the complementary diagnostic value for human pancreatic carcinoma and may increase the diagnostic sensitivity to 97.5%.

Conclusions

Galectin-3 is overexpressed in pancreatic carcinoma tissues, and it is correlated with the tumor differentiation. Serum galectin-3 is higher in cases with pancreatic carcinoma than in benign pancreatic diseases and healthy persons. Combined determination of serum galectin-3, CEA and CA199 may improve the diagnostic power for pancreatic carcinoma.     

肝细胞癌和慢性乙型肝炎患者血清sFRP-1和β-catenin水平及临床意义

目的：探讨肝细胞癌（hepatocellular carcinoma, HCC）和慢性乙型肝炎（chronic hepatitis B,CHB）患者血清分泌型卷曲相关蛋白-1（secreted frizzled-related proteins, sFRP-1）和β-catenin水平及临床意义。方法采用ELISA法检测36例HCC、36例CHB和36例正常人血清sFRP-1和β-catenin水平,应用Spearman相关分析,分析血清sFRP-1和β-catenin水平与年龄、丙氨酸氨基转移酶（ALT）、白蛋白和总胆红素等的相关性。结果 HCC和CHB患者血清sFRP-1水平分别为（1136.28±332.43）pg/ml和（1194.53±156.84）pg/ml,均显著低于正常人[（1477.26±563.12）pg/ml,P＜0.05];HCC患者血清β-catenin水平为（527.2±20.9）pg/ml,显著高于正常人和CHB患者[分别为（369.8±21.5）pg/ml和（374.0±8.3）pg/ml,P＜0.05];HCC和CHB患者血清sFRP-1和β-catenin水平与年龄、ALT、白蛋白、总胆红素无显著相关性。结论肝细胞癌和慢性乙型肝炎患者血清sFRP-1降低,而肝细胞癌患者血清β-catenin水平升高。     

Preventive effect of Qianggan-Rongxian Decoction on rat liver fibrosis

AIM： To study the preventive effects of Qianggan-Rongxian Decoction on liver fibrosis induced by dimethylnitrosamine （DMN） in rats.
METHODS： Male Wistar rats were randomly divided into hepatic fibrosis model group, control group and 3 treatment groups （12 rats in each group）. Except for the normal control group, all the rats received 1% DMN （10 μL/kg body weight, i.p）, 3 times a week for 4 wk. The rats in the 3 treatment groups including a high-dose DMN group （10 mL/kg）, a medium-dose DMN group （7 mL/kg）, and a low-dose DMN group （4 mL/kg） were daily gavaged with Qianggan-Rongxian Decoction, and the rats in the model and normal control groups were given saline vehicle. Enzyme-linked immunosorbent assay （ELISA） was used to determine the changes in serum hyaluronic acid （HA）, laminin （LN）, and type IV collagen levels. Serum alanine aminotransferase （ALT） and aspartate aminotransferase （AST） levels were measured using routine laboratory methods. Pathologic changes, particularly fibrosis, were examined by hematoxylin and eosin （HE） and Sirius red staining. Hepatic stellate cells （HSC） were examined by transmission electron microscopy.
RESULTS： Compared with the model control group, the serum levels of HA, LN, type Ⅳ collagen, ALT and AST were decreased markedly in the other groups after treatment with Qianggan-Rongxian Decoction, especially in the medium-dose DMN group （P 〈 0.05）.Moreover, the area-density percentage of collagen fibrosis was lower in the Qianggan-Rongxian Decoction treatment groups than in the model group, and a more significant drop was observed in the medium-dose DMN group （P 〈 0.05）.
CONCLUSION： Qianggan-Rongxian Decoction can inhibit hepatic fibrosis due to chronic liver injury, delay the development of cirrhosis, and notably ameliorate liver function. It may be used as a safe and effective thera-peutic drug for patients with fibrosis.